BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co. Ltd. have signed an agreement to supply Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval. Initial supply will be delivered from BioNTech’s production facilities in Germany.     “We would like to thank the Chinese government and National Medical Products Administration for their commitment and trust in our vaccine development efforts to he...